RxDoctor Payments Data

Daniel Amaez, MD

Cardiovascular Disease · Wellington, FLNPI 1518123264

Payments from drug & device makers

$5,834in general payments, 2019–2025

Across 346 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$898
  • Abbott$642
  • Johnson & Johnson$550
  • Boehringer Ingelheim$327
  • AstraZeneca$289
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,820100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,834 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$645,282
Medicare patients
2,028
Services billed
5,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban438$444,305
Repatha SureclickEvolocumab207$151,486
EntrestoSacubitril/Valsartan111$126,786
XareltoRivaroxaban113$117,906
JardianceEmpagliflozin37$38,450
BrilintaTicagrelor36$37,178
MultaqDronedarone Hcl18$26,314
WegovySemaglutide14$18,173
Praluent PenAlirocumab21$14,044
FarxigaDapagliflozin Propanediol12$11,172
Metoprolol Succinate405$5,455
Atorvastatin Calcium347$3,460
Rosuvastatin Calcium267$3,452
Diltiazem 24hr Er (Cd)Diltiazem Hcl86$2,931
Prasugrel Hcl17$2,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$234$444,305438 claims
NovartisEntresto$898$126,786111 claims
Johnson & JohnsonXarelto$550$117,906113 claims
AstraZenecaBrilinta, Farxiga$289$48,35048 claims
Boehringer IngelheimJardiance$327$38,45037 claims
Sanofi-aventis U.S. LLCMultaq$286$26,31418 claims
Novo NordiskWegovy$61$18,17314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →